Press
NAVAN Closes Seed Funding Round – Investors include Amgen Ventures, HTGF and Hemi Ventures
NAVAN Technologies, Inc. (NAVAN), a privately-held biotechnology company enabling the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform, announced it had closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi Ventures, and other institutional and private investors. Based on technology exclusively licensed from Stanford University, NAVAN is also supported by a National Science Foundation STTR Phase II award a
Press
Drug discovery technology start-up DyNAbind secures seed financing
DyNAbind’s Dynamic DNA-Encoded Library technology platform allows hundreds of millions of chemical structures to be simultaneously screened and optimized against a potential drug target protein. This innovation continues to be driven forward with investment from the High-Tech Gründerfonds (HTGF), Technologiegründerfonds Sachsen (TGFS) and existing shareholder TUDAG - TU Dresden AG.
Finding a new drug candidate can be like finding a needle in a haystack. Imagine that instead of checking one
Press
Legal AI Start-up rfrnz receives seven-figure investment for contract analysis
The Munich-based start-up rfrnz automates contract analysis with the help of artificial intelligence. By using it lawyers can not only save costs and time, but also minimize errors and upgrade for the digital age. High-Tech Gründerfonds (HTGF), UnternehmerTUM Initiative for Industrial Innovators and two other investors support rfrnz with a seven-figure seed investment. The funds will be used to finance and advance the growth and further development of the product and team.
The analysis of con
Press
AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091
AMAL’s lead candidate, ATP128, will be evaluated in combination with Boehringer Ingelheim’s anti-PD-1 antibody BI754091 in a Phase Ib trial (‘KISIMA-01’)
Combination will be studied in patients with Microsatellite Stable (MSS) stage IV colorectal cancer
AMAL retains full development and commercialization rights to ATP128 and the KISIMA technology platform
AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces
Press
miRdetect Receives Seed Financing – Consortium Invests Seven-Digit Amount in Serum Marker for Testicular Cancer Detection
High-Tech Gründerfonds (HTGF), BAB Beteiligungs- und Managementgesellschaft Bremen mbH (BBM) and a private investor invest in Bremen start-up miRdetect
miRdetect develops an innovative and accurate test method for the detection of testicular cancer
Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a seven-figure sum in the start-up company miRdetect located in Bremen, and founded in 2016. The company founders Meike Spiekermann and Dr. Nina Winter were
Press
ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer
ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by BPI France, Schroder Adveq and the German High-Tech Gründerfonds (HTGF).
Markus L.E. Ewert, PhD, MBA has joined the company as Chief Executive Officer. M
Press
Upcoming MedTech Radar Live 2019 event organized by BVMed, Earlybird, High-Tech Gründerfonds and medtech zwo featured in the 12th MedTech Radar publication:
How can innovations reach hospitals? What is the potential of new digital solutions and which are the current challenges that start-ups have to overcome to facilitate adoption? At the event "MedTech Radar Live 2019" on June 5th in Berlin these questions will be among those discussed by experts from the medtech sector. A preview of the event is provided by the joint media service "MedTech Radar" of the German Medical Technology Association (BVMed), Earlybird Venture Capital, the High-Tech Gründe
Press
Berlin-based music-learning platform Skoove raises €3M in new investment round
Skoove, a Berlin-based music tech start-up has successfully secured an investment of €3M. Caparuca, MGO Digital Ventures and Ringier Digital Ventures join existing investors Egora Holding, IBB Beteiligungsgesellschaft and High-Tech Gründerfonds (HTGF).
Skoove, the piano e-learning platform founded in 2014, is on a mission to make music education accessible to everyone regardless of income or education. With genuine guidance and feedback from the app (available on iOS and in browser), peopl
Press
High-Tech Gründerfonds portfolio company Immunic Therapeutics to trade on NASDAQ
Reverse takeover enables Immunic to secure US listing on world’s largest electronic stock exchange
Existing Immunic investors invested a further EUR 26.7 million as part of NASDAQ listing
Founded in Bavaria, Germany, in 2016, the biotech start-up develops novel treatments for chronic inflammatory diseases
High-Tech Gründerfonds has been at Immunic’s side from the very beginning
Immunic’s listing on the NASDAQ has been achieved through a reverse takeover, with the company slippin
Press
Successful exit for High-Tech Gründerfonds: Brainlab acquires medical robotics start-up Medineering
High-Tech Gründerfonds has partnered the start-up since the seed round in 2014
Medineering develops robotic assistance systems for use in operating theatres
Ulrike Kalapis (HTGF): “Medineering is a real success story. It took the team only a few years to develop a sophisticated, innovative product, and now bring it to market.”
High-Tech Gründerfonds and other investors are selling all of their shares in the robotics start-up Medineering GmbH, based in Munich, to Brai
Press
Artificial Intelligence for faster and more reliable radiological findings
The use of Artificial Intelligence makes medical findings faster and more reliable:
mediaire GmbH is developing innovative methods that help radiologists detect neurodegenerative diseases, such as Alzheimer's or Multiple Sclerosis, earlier and faster. The High-Tech Gründerfonds (HTGF), together with a group of private investors, is investing a large six-digit amount in the growth of this Berlin-based start-up.
The goal of mediaire GmbH is to increase patient safety and facilitate everyday
Press
Coinlend receives HTGF seed funding for its AI-based lending platform tailored to the cryptocurrency market
Coinlend's AI-based technology automates, monitors and maximizes interest
generation through margin funding - the secure financing of leveraged trading
positions - in the cryptocurrency sector. In February 2019, the HTGF did invest in the
company in the six-figure range.
The major trading exchanges in the cryptocurrency sector offer their users the opportunity to
lend their funds to day traders in the form of short-term loans in addition to the actual trading
in crypto and fiat currencie
Press
bookingkit Secures Multi-Million Euro Financing and Pushes Further Expansion in Europe
Series C Funding Round in mid-single-digit million euro amount
Intermedia Vermögensverwaltung and family of companies Müller Medien are once
again lead investors and seed investor High-Tech Gründerfonds expands its commitment
Expansion into new European markets planned for this summer
Existing business in Germany, Austria, Switzerland, Italy and France to be further developed
bookingkit achieves profitability in Germany, Austria and Switzerland for the first time
Press
EUR 3 million in series A for the growth and development of Cytena GmbH
The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics.
EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena's single-cell printers.
Freiburg-based Cytena GmbH successfully completes another financing round. I
Press
Karlsruhe-based AI testing start-up retest secures six-figure seed investment by High-Tech Gründerfonds (HTGF)
Innovative technology solves problems with software tests through an AI-supported and agile automation solution
Today's software systems are complex, and many internal dependencies remain unclear. As a result, changes to the software lead to undesired side effects that often go unnoticed, i.e. an existing and already tested functionality is impaired. In order to prevent such regressions, software must be tested again and as completely as possible after each change. Previous automation solutions
Press
IPlytics, the AI Startup tackling patent analytics, raises several millions in financing
Berlin-based IPlytics, the company disrupting patent analytics with an artificial intelligence (AI)-powered patent analytics software, receives several million Euros in venture capital as part of a financing round led by German VC investor eCAPITAL, with High-Tech Gründerfonds (HTGF) joining the round as existing shareholder. The capital will be used for the further technical development of the software as well as the expansion of sales into international markets, in particular USA, Korea and J